Updated employee announcements, business news, awards and recognition in the industry today.
People
SynteractHCR has appointed four new Senior-Level Managers to its International Leadership Team. Miguel Fuentes joins as Executive Director, Service Delivery; Patrick F. Loebs, MSW, MPH, as Senior Regulatory Affairs Manager; Katharina Grote, as Finance Director, and Ewelina Mazur-Janik, MD, as Medical Monitor.
Worldwide Clinical Trials has appointed Margo Holland as its Vice President of Global Quality.
Bracket, a clinical trial technology and specialty services provider, announced the addition of Jennifer Peters to its team as the company's new Senior Vice President and General Manager for the Scientific Services division.
MedAvante, Inc., a provider of technology-based clinical trial services for treatments of central nervous system (CNS) diseases, announced that Susan Vallow, RPh MBA MA, has assumed a new position as Vice President, Patient eSolutions, joining MedAvante from GSK where she was Senior Director and Head of Patient Focused Outcomes.
Greenleaf Health, an FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical and medical device companies, announced that John Jenkins, MD, has joined the firm as Principal, Drug and Biological Products.
INC Research, a global Phase I to IV CRO, announced the appointment of Eric Paul Pâques to the Company’s Board of Directors. Pâques joins the INC Research Board as an Independent Director and will be a Class I Director serving a term ending at the company’s 2018 Annual Meeting.
Almac Diagnostics has announced the appointment of Leeona Galligan, PhD, FRCPath to the position of Vice President, UK Operations.
Business
Chiltern announces the opening of its new process and technology center in Bangalore, India. In total, the company’s offices in India will be able to support more than 600 employees and give Chiltern substantial capacity to advance operations as needed.
endpoint Clinical launches the 500th clinical trial on its proprietary full-service IRT solution, PULSE.
Beaufort, LLC a CRO and consultancy, has obtained ISO 9001:2015 certification. The certification demonstrates that Beaufort provides quality services to the life sciences industry in its clinical research, regulatory affairs, quality and staffing solutions.
Awards
A 2017 IoT Evolution Business Impact Award will be presented to Sprint and its client, BioTelemetry, Inc., by TMC and Crossfire Media.
Recognition
PAREXEL has been named to Training Magazine’s annual “Training Top 125,” honored for developing creative and effective learning and development initiatives for its global workforce.
Worldwide Clinical Trials has been ranked as the industry’s #1 provider of Overall Contract Research, which includes non-clinical research services, in the “2017 Nice Insight Preclinical and Clinical Contract Research Survey.” The survey examines market perceptions of CROs using data collected from key industry executives.
KCR, a German CRO providing clinical development solutions for the pharma, biotech and medical device industries, celebrates its 20-year anniversary of contributing to clinical R&D.
Clintec International, announces the launch of its new brand identity to coincide with their 20th anniversary.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.